419 related articles for article (PubMed ID: 29617965)
1. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
4. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
[TBL] [Abstract][Full Text] [Related]
7. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
[TBL] [Abstract][Full Text] [Related]
8. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
[TBL] [Abstract][Full Text] [Related]
9. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
10. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries.
Kowada A
Travel Med Infect Dis; 2016; 14(5):489-498. PubMed ID: 27238907
[TBL] [Abstract][Full Text] [Related]
13. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
Holland DP; Sanders GD; Hamilton CD; Stout JE
Am J Respir Crit Care Med; 2009 Jun; 179(11):1055-60. PubMed ID: 19299495
[TBL] [Abstract][Full Text] [Related]
14. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
[TBL] [Abstract][Full Text] [Related]
15. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV.
Shin H; Jo Y; Chaisson RE; Turner K; Churchyard G; Dowdy DW
J Int AIDS Soc; 2020 Oct; 23(10):e25629. PubMed ID: 33107219
[TBL] [Abstract][Full Text] [Related]
17. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
Holland DP; Sanders GD; Hamilton CD; Stout JE
PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India.
Kapoor S; Gupta A; Shah M
Int J Tuberc Lung Dis; 2016 Jan; 20(1):85-92. PubMed ID: 26688533
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
Cao X; Guo T; Xin H; Du J; Yang C; Feng B; He Y; Shen L; Di Y; Li Z; Chen Y; Liang J; Jin Q; Wang L; Gao L
Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):809-820. PubMed ID: 38383889
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
